A Sector Priced for Doom – Why Healthcare Offers an Unmissable Opportunity
Healthcare is one of the most mispriced sectors, trading near its lowest valuations in over 30 years. Why?
In the world of investing, opportunities arise from market mispricings. And right now, healthcare is one of the most mispriced sectors, trading near its lowest valuations in over 30 years.
Why is this happening?
For nearly three decades, healthcare kept pace with technology, even during the tech supercycle that transformed the global economy. From the internet to cloud computing, healthcare managed to evolve alongside technological advancements, improving lives through innovation. Yet, over the past five years, the divergence between tech and healthcare stocks has been staggering. While tech has soared, healthcare has lagged significantly.
But it’s not all bad news. Health care is inexpensive, trading near historical lows, and the gap is not just a curiosity—it’s a real opportunity.
What’s driving the undervaluation?
Much of the recent sell-off stems from the so-called “patent cliff.” With some of Big Pharma’s top-selling drugs approaching patent expiration, there’s uncertainty around future revenue streams. However, this uncertainty creates opportunities, as the industry is doubling down on R&D, acquisitions, and partnerships to compensate for these revenue gaps.
Biotech is at the heart of this shift. Despite sentiment swings, biotech’s valuation is now among the lowest compared to its high profitability. Investors have been ignoring this opportunity, but we’re not. The industry is still posting the highest Return on Equity (ROE) in the healthcare space, which makes it an incredibly undervalued play.
In the chart below, you can see a clear, intuitive relationship between valuation (Price to Book) and profitability (Return on Equity). It makes sense: the higher a company’s ability to generate returns on its equity, the more investors are typically willing to pay for each dollar of its book value. High-ROE businesses deserve higher multiples because they compound capital faster.
As we look at the future, we see innovation in fields like smarter cancer drugs, Alzheimer’s treatment, and gene editing as catalysts that will drive the sector forward. Once breakthroughs emerge, capital will flow toward the companies that can scale these innovations effectively.
In short, healthcare’s current discount offers a rich opportunity for patient investors.
Our Tier One and Alpha Tier Model Portfolios keep punching out all-time highs. The fuel? Exactly what we’ve been pounding the table on: precious metals (still the cleanest expression of Liquidity + Fiscal Dominance), disruptive tech, industrial-metals miners, China, crypto, and sidecar themes like uranium miners. This is the logical corollary of our overriding Market View since the inaugural editions: a new inflationary regime pushing alternative assets (and select equities) to new highs. As our Model Portfolios in those tiers show, this thesis isn’t contrarian anymore... it’s in the returns.
If you want the full package—my working checklists, trigger levels, invalidations, and the Model Portfolio table with weights for new subscribers—join the premium tier at ➡️ VMF Research.
